All In Biotech

Drug Trial Radar · NCT07940439

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

An Open, Single-Arm, Multicenter Phase I/II Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2030

Study completion Jun 2031

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety and tolerability of HRS-9308 tablet in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of HRS-9308.

Conditions

  • Solid Tumor

Interventions

  • HRS-9308 TabletDrug

    HRS-9308 tablet, with different doses, in Stage I, Stage II or Stage III.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: From Day 1 to 40 days after the last dose.
  2. Dose-limiting toxicity (DLT)Time frame: From Day 1 to 12 months.
  3. Maximum tolerated dose (MTD)Time frame: From Day 1 to 12 months.
  4. Recommended dose for Phase II clinical studies (RP2D)Time frame: From Day 1 to 12 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.